Cidara Therapeutics (CDTX) Tops Q3 EPS by 6c

Cidara Therapeutics (NASDAQ: CDTX) reported Q3 EPS of ($0.09), $0.06 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $12.72 million versus the consensus estimate of $8.14 million.

For earnings history and earnings-related data on Cidara Therapeutics (CDTX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Investing.com’s stocks of the week
• Aspire Biopharma to acquire automotive supplier for $30 million